iTeos Therapeutics, Inc. (ITOS) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
321 Arsenal Street
Watertown, MA 02472-5710
United States of America (the)
Phone
339 217 0161
Sector
Healthcare
Industry
Biotechnology
Employees
173
First IPO Date
July 24, 2020
| Name | Title | Pay | Year Born |
| Michel Detheux | President, Chief Executive Officer & Director | 1.12M | 1967 |
| Matthew Gall | Chief Financial Officer | 648,001 | 1977 |
| Matthew A. Call | Chief Operating Officer | 725,481 | 1973 |
| David Feltquate | Chief Medical Officer | 774,444 | N/A |
| Yvonne McGrath | Chief Scientific Officer | 0 | 1974 |
| Philippe Brantegem | Chief People Officer | 0 | N/A |
| Adi Osovsky | Executive Vice President of Legal | 0 | N/A |
iTeos Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm, concentrating on the discovery and advancement of immuno-oncology therapies for patients. The company's pipeline includes two principal investigational drugs: inupadenant, a small molecule designed as an antagonist of adenosine A2AR, which is currently undergoing Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT (T-cell immunoreceptor with Ig and ITIM domains), presently in Phase 1/2 clinical assessment. Furthermore, EOS-448's mechanism involves engaging the Fc gamma receptor (FcγR) to activate dendritic cells and macrophages, thereby promoting antibody-dependent cellular cytotoxicity (ADCC). Established in 2011, iTeos Therapeutics, Inc. is based in Watertown, Massachusetts.